Overview

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Phase:
Phase 3
Details
Lead Sponsor:
Catalyst Pharmaceuticals, Inc.
Treatments:
3,4-diaminopyridine
Amifampridine